| 摘要 |
<p>This invention features combination therapies that include a composition that activates lymphotoxin-beta receptor signaling in combination with one or more other chemotherapeutic agents, as well as therapeutic methods and screening methods for identifying agents that in combination with a lymphotoxin-beta receptor agonist agent have a supra-additive effect on tumor inhibition.</p> |
